Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT04279496
Enrolling by invitation Observational

Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry

NCT04279496 · tracked via the Priya Life Science USA tracker
Sponsor
Cleerly, Inc
Phase
Observational
Started
2020-06-01
Last updated
2026-06-05

Condition(s) studied

Coronary Artery Disease

Study summary

The overall objective of CONFIRM2 is to perform the largest cardiovascular phenotype outcomes study ever.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>18 years * Undergoing clinically indicated CCTA with \>64-detector row CT * Signed informed consent, including of release of medical information, long term follow-up and Health Insurance Portability and Accountability Act (HIPAA) documentation Exclusion Criteria: * Individuals unable to provide informed consent * Non-cardiac illness with life expectancy \< 2 years * Pregnancy

Primary outcome measure(s)

  • Coronary CT Angiography EvaluatioN For Clinical Outcomes — June 2020- June 2022
    Examined the totality of information visualized by coronary CT angiography (CCTA) for optimal refinement of prognostic risk stratification

Trial sites (1)

FacilityCityRegionStatus
University of Virginia Charlottesville Virginia

More Cleerly, Inc. trials in the USA

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events Recruiting
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD Active, not recruiting

Other trials for the same condition

AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management Active, not recruiting
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE) Active, not recruiting
RADIQAL Study (Radiation Dose and Image Quality Trial) Active, not recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI) Recruiting
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04279496 on ClinicalTrials.gov ↗ ← All trials in the USA